(43,808) (19,483)
Interest income 897 1,091
Interest expense (3,787) (3,268)
Other expense (12) (3,069)
Gain on sale of product rights - 5,145
Net loss $(46,710) $(19,584)
Net loss per share, basic and
diluted $(1.97) $(851.48)
Weighted-average common shares used
in computing net loss per share, basic
and diluted 23,743 23
JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET
(In thousands)
(Unaudited)
Three Months Ended March 31,
2008 2007
Xyrem $11,341 $8,624
Antizol 2,643 2,636
Cystadane - 365
Total $13,984 $11,625
JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
March 31, December 31,
2008 2007
ASSETS
Current assets:
Cash and cash equivalents $100,771 $102,945
Restricted cash 1,998 1,939
Mar
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Medimetriks Pharmaceuticals, Inc. Begins Operations2.
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results3.
Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period4.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT5.
Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 20086.
Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing7.
Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition8.
GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development9.
Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)10.
Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC11.
Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights